Response Genetics, Inc

Equities

RGDXQ

US76123U1051

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 17:32:09 15/05/2023 BST			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-.--%

2016	Response Genetics, Inc Bankruptcy Case Dismissed	CI
2016	Motion for Case Dismissal Filed for Response Genetics, Inc	CI

Response Genetics, Inc Appoints Kevin R. Harris as Vice President and Chief Financial Officer

June 17, 2013 at 08:01 pm

Response Genetics Inc. announced that it has appointed Kevin R. Harris, who has served as the Interim Chief Financial Officer of the company since August 20, 2012, as Vice President and Chief Financial Officer of the company effective on June 12, 2013. Prior to joining the company as Interim Chief Financial Officer, Mr. Harris, served as Chief Financial Officer of CyberDefender Corporation from January 2009 to August 2012 and as Chief Operating Officer of Statmon Technologies Corp. from April 2004 to January 2009.

Latest news about Response Genetics, Inc

Response Genetics, Inc Bankruptcy Case Dismissed	18/04/16	CI
Motion for Case Dismissal Filed for Response Genetics, Inc	22/03/16	CI
Response Genetics, Inc Announces Resignation of David Wurzer as Non-Executive Director	20/11/15	CI
Response Genetics, Inc Announces Board Changes	14/10/15	CI
Cancer Genetics, Inc. completed the acquisition of substantially all the assets and operations of Response Genetics, Inc.	08/10/15	CI
Motion for Asset Sale Approved for Response Genetics, Inc	01/10/15	CI
Notice for Auction Cancellation Filed by Response Genetics, Inc	28/09/15	CI
Final DIP Financing Approved for Response Genetics, Inc	08/09/15	CI
Bidding Procedure Approved for Response Genetics, Inc	28/08/15	CI
Motion for Asset Sale Filed by Response Genetics, Inc	14/08/15	CI
Response Genetics, Inc will Change its Ticker to RGDX.Q from RGDX	11/08/15	CI
Interim DIP Financing Approved for Response Genetics, Inc	11/08/15	CI
Cancer Genetics, Inc. entered into an agreement to acquire substantially all the assets and operations from Response Genetics, Inc for $13.8 million.	09/08/15	CI
Response Genetics, Inc Filed for Bankruptcy	09/08/15	CI
Response Genetics, Inc(OTCPK:RGDX) dropped from NASDAQ Composite Index	19/07/15	CI
Greece and China expose limits of 'whatever it takes'	08/07/15	RE
Response Genetics, Inc(OTCPK:RGDX.Q) dropped from S&P TMI Index	08/07/15	CI
Response Genetics, Inc(OTCPK:RGDX.Q) dropped from CRSP US Total Market Index	07/07/15	CI
Response Genetics, Inc(OTCPK:RGDX.Q) dropped from MSCI Acwi + Frontier Markets(acwi Fm) All Cap Index	07/07/15	CI
Response Genetics, Inc. Enters into a Third Amendment to its Credit Agreement	01/07/15	CI
Response Genetics, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015	14/05/15	CI
Response Genetics, Inc. Announces Unaudited Consolidated Financial Results for the Fourth Quarter and Full Year Ended December 31, 2014	01/04/15	CI
Response Genetics, Inc Auditor Raises 'Going Concern' Doubt	30/03/15	CI
Response Genetics, Inc Announces Resignation of Stephanie H. Astrow as Vice President, Research and Development	20/03/15	CI
Response Genetics, Inc. Enters into First Amendment to Credit Agreement	06/02/15	CI

Chart Response Genetics, Inc

Duration

Period

More charts

Company Profile

Response Genetics, Inc. is a life science company. The Company is engaged in the research, development, marketing and sale of pharmacogenomic tests for use in the treatment of cancer. To generate pharmacogenomic information from patient specimens for these tests, the Company uses its own methods for the extraction and analysis of nucleic acids and accessing the genetic information available from each patient sample. The Company's platforms include analysis of single biomarkers using the polymerase chain reaction method, as well as gene interrogation using microarray methods and fluorescence in situ hybridization (FISH) from paraffin or frozen tissue specimens. The Company is engaged in selling ResponseDX diagnostic testing products. The Company provides pharmacogenomic clinical trial testing services to pharmaceutical companies in the United States, Asia and Europe.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
RESPONSE GENETICS, INC	-.--%	38
MODERNA, INC.	+40.80%	53.67B
LONZA GROUP AG	+35.14%	38.86B
IQVIA HOLDINGS INC.	-8.05%	38.76B
CELLTRION, INC.	-8.98%	27.27B
ICON PUBLIC LIMITED COMPANY	+10.69%	25.91B
ALNYLAM PHARMACEUTICALS, INC.	-16.21%	20.29B
UNITED THERAPEUTICS CORPORATION	+31.00%	12.78B
MEDPACE HOLDINGS, INC.	+28.51%	12.18B
BIO-TECHNE CORPORATION	-1.67%	11.96B

Other Biotechnology & Medical Research